oligonucleotides

Agilent said it has uncovered new and relevant facts in its intellectual property lawsuit against Twist and its Founder and CEO Emily LeProust.

The financing will support growth in Maravai's three life science segments: bioprocess impurity testing, oligonucleotide synthesis, and protein detection.

IDT will operate as a standalone company within Danaher's Life Sciences segment after the close of the deal, which is expected to occur in mid-2018.

The company will integrate the oligonucleotide manufacturer with two of its existing sections to form a new Nucleic Acid Chemistry business unit.

The acquisition of GeneWorks' oligo business widens IDT's reach in the Asia-Pacific region, the company said.

Agilent filed a lawsuit against Twist nearly a year ago, alleging that Twist Cofounder and CEO Emily LeProust had stolen DNA oligonucleotide synthesis technology. 

Single nucleus sequencing analysis of triple-negative breast tumors indicated that copy number changes occur in bursts early in tumor evolution.

In its court filing, the company said Twist Founder and CEO Emily LeProust stole its technology and breached her confidentiality agreements.

The new 8,000-square-foot building will support oligonucleotide manufacturing for molecular biology applications such as qPCR, next-generation sequencing, and synthetic biology.